{"id":29122,"date":"2025-03-12T15:23:56","date_gmt":"2025-03-12T07:23:56","guid":{"rendered":"https:\/\/flcube.com\/?p=29122"},"modified":"2025-03-12T15:23:58","modified_gmt":"2025-03-12T07:23:58","slug":"sun-novo-partners-with-youjia-biomedical-to-develop-antibody-oligonucleotide-conjugate-for-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29122","title":{"rendered":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases"},"content":{"rendered":"\n<p>China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688621:SHA\">SHA: 688621<\/a>) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.<\/p>\n\n\n\n<p><strong>Partnership Details<\/strong><br>The partnership between Sun-Novo and Youjia Biomedical focuses on the research and development of AOCs, a novel class of therapeutic agents that combine the targeting capabilities of antibodies with the therapeutic potential of oligonucleotides. This innovative approach holds promise for improving the treatment landscape for metabolic diseases, which affect millions of patients worldwide.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot&#8230;<\/p>\n","protected":false},"author":1,"featured_media":29123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1262,2604,2190],"class_list":["post-29122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-sha-688621","tag-sun-novo-pharmaceutical-research","tag-youjia-biomedical-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29122\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29122\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T07:23:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-12T07:23:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases\",\"datePublished\":\"2025-03-12T07:23:56+00:00\",\"dateModified\":\"2025-03-12T07:23:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122\"},\"wordCount\":127,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1212-png.avif\",\"keywords\":[\"SHA: 688621\",\"Sun-Novo Pharmaceutical Research\",\"Youjia Biomedical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29122#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29122\",\"name\":\"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1212-png.avif\",\"datePublished\":\"2025-03-12T07:23:56+00:00\",\"dateModified\":\"2025-03-12T07:23:58+00:00\",\"description\":\"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29122\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1212-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1212-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29122#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29122","og_locale":"en_US","og_type":"article","og_title":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases","og_description":"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.","og_url":"https:\/\/flcube.com\/?p=29122","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-12T07:23:56+00:00","article_modified_time":"2025-03-12T07:23:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29122#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29122"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases","datePublished":"2025-03-12T07:23:56+00:00","dateModified":"2025-03-12T07:23:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29122"},"wordCount":127,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29122#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","keywords":["SHA: 688621","Sun-Novo Pharmaceutical Research","Youjia Biomedical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29122#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29122","url":"https:\/\/flcube.com\/?p=29122","name":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29122#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29122#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","datePublished":"2025-03-12T07:23:56+00:00","dateModified":"2025-03-12T07:23:58+00:00","description":"China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29122#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29122"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29122#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","width":1080,"height":608,"caption":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29122#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sun-Novo Partners with Youjia Biomedical to Develop Antibody-Oligonucleotide Conjugate for Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1212-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29122"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29122\/revisions"}],"predecessor-version":[{"id":29124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29122\/revisions\/29124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29123"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}